Results 151 to 160 of about 17,658 (223)

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. [PDF]

Nat Cancer
Perez KJ, Dias Costa A, Jordan A, Karasic TB, Elganainy D, Kim S, Yuan C, Gui DY, Tan R, Hong SC, Wang X, Cristea S, Coleman E, Truitt M, Oh TG, Zheng H, Furniss CS, Brais L, Bird A, Remland J, Gocheva V, Thalappillil JS, Anderson M, Cleary JM, Enzinger A, Giannakis M, Ng K, Rubinson DA, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter PS, Raghavan S, Yeh JJ, Von Hoff D, Liddle C, Downes M, Evans RM, O'Dwyer P, Aguirre A, Nowak JA, Wolpin BM.   +45 more
europepmc   +1 more source

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. [PDF]

Sci Rep
Sezgin Y, Karhan O, Aldemir MN, Ürün M, Erçek BM, Urakcı Z, Arvas H, Tunç S, Erdem M, Yerlikaya H, İleri S, Aydın İ, Bicer A, Kömüroğlu AU, Majidova N, Gökçek S, Demir H, Yıldız S, Akbaş S, Özen E, Kahya BU, Sali M, Anık H, Aykut T, Araz M, Alkan A, Özçelik M, Sakin A, Aykan MB, Mehtıyev M, Demir B, Başer MN, Sönmez M, Gültürk İ, Avcı N, Urvay S, Arıcı MÖ, Kalender ME, Yıldırım M, Solmaz AA, Gürbüz M, Ergün Y.   +41 more
europepmc   +1 more source

NSCLC: Verträglichere Therapie mit nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
openaire   +1 more source

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE. [PDF]

NPJ Breast Cancer
Shimoi T, Shibata N, Kitada M, Tsuneizumi M, Yamamoto M, Ozaki Y, Fujimoto Y, Akiyoshi S, Hashimoto N, Yamaguchi M, Yamamoto Y, Masuda N, Tada H, Yamanaka T, Kikawa Y, Taira T, Nakagawa S, Takahashi T, Oba MS, Niikura N.   +19 more
europepmc   +1 more source

Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study. [PDF]

Front Pharmacol
Liu Y, Li Y, Li X, Zhang H, Liu X, Chen P.   +5 more
europepmc   +1 more source

Influence of Consecutive Nab-Paclitaxel Chemotherapy Cycles on Gut Microbiota and Pharmacokinetic Behavior. [PDF]

Technol Cancer Res Treat
Zhang X, Xie W, Zhang Y, Yuan Y, Xu J, Liu J.   +5 more
europepmc   +1 more source

Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2). [PDF]

Front Immunol
Wang X, Zhang P, Cao D, Xu H.
europepmc   +1 more source

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. [PDF]

Cancer Commun (Lond)
Li H, Chen M, Huang R, Rong Q, Hao J, Zheng Q, Su Y, Shu D, Zhang Y, Yang W, Lei X, Cai Y, Xue C, An X, Shi Y.   +14 more
europepmc   +1 more source

Correction: Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study. [PDF]

J Cancer Res Clin Oncol
Li S, Xian B, Cui L, Wu L, Fang C, Yang F, Li J.   +6 more
europepmc   +1 more source